REGN Financial Facts
Net loss before income tax benefit: 365.88MNet product sales: 857.47M
See Full Income Statement
Common Stock: 2K
Other assets: 20.71M
See Full Balance Sheet
Regeneron Pharmaceuticals, Inc. (REGN) Earnings
|
Expand Research on REGN
| Next EPS Date | 5/2/24 | EPS Growth Rate | +0.3% |
|---|---|---|---|
| Average EPS % Beat Rate | +10.8% | Revenue Growth Rate | +2.2% |
| Average % Move 1-Wk after EPS | -0.4% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 8/2/18 |  |
Q218 | $5.45 | $4.70 | +$0.75 | $1.61B | $1.56B | = |  | | Details |
| 11/5/19 | |
Q319 | $6.67 | $6.36 | +$0.31 | $2.05B | $1.99B | N/A | | | Details |
| 5/4/17 | |
Q117 | $2.92 | $3.07 | -$0.15 | $1.32B | $1.3B | = | | | Details |
| 5/5/20 | |
Q120 | $6.60 | $6.13 | +$0.47 | $1.83B | $1.76B | N/A | | | Details |
| 8/3/22 | Q222 | $9.77 | $8.60 | +$1.17 | $2.86B | $2.79B | N/A | | | Details | |
| 8/3/23 | Q223 | $10.24 | $9.85 | +$0.39 | $3.16B | $3.03B | N/A | | | Details | |
| 2/6/20 | |
Q419 | $7.50 | $6.92 | +$0.58 | $2.17B | $2.11B | N/A | | | Details |
8/4/15  |
|
Q215 | $2.89 | $2.77 | +$0.12 | $999M | $887.81M | N/A | | | Details |
